AstraZeneca shares fell sharply following reports the drugmaker is considering an acquisition of Bristol Myers Squibb. Analyst Fazeli expressed skepticism, stating the potential deal 'makes no sense' for AstraZeneca.
AstraZeneca Shares Plunge on Bristol Myers Squibb Acquisition Talk
|1 min read
pharmaceuticalsM&Astock-decline
